Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy

International Journal of Cancer

Volumn 112, Issue 1, 2004, Pages 14-25

  Santin, Alessandro D ^a,d   Zhan, Fenghuang ^a   Bellone, Stefania ^a   Palmieri, Michela ^a   Cane, Stefania ^a   Bignotti, Eliana ^a   Anfossi, Simone ^a   Gokden, Murat ^a   Dunn, Donna ^a   Roman, Juan J ^a   O'Brien, Timothy J ^a   Tian, Erming ^a   Cannon, Martin J ^b   Shaughnessy Jr , John ^a   Pecorelli, Sergio ^c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF ARKANSAS MEDICAL CENTER   (United States)

Author keywords

Gene expression profiling; Serous papillary ovarian cancer

Indexed keywords

CD24 ANTIGEN; CLAUDIN; FORMALDEHYDE; ISOPROTEIN; KALLIKREIN; LAMININ; LIPOCALIN; OLIGONUCLEOTIDE; OSTEOPONTIN; PARAFFIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN S 100; PROTEINASE; RAS PROTEIN; THROMBOSPONDIN 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA3; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; DNA MICROARRAY; DOWN REGULATION; EPITHELIUM; FEMALE; FLOW CYTOMETRY; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; GROWTH RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOLECULAR BIOLOGY; MULTIGENE FAMILY; OVARY CARCINOMA; OVARY TUMOR; PAPILLOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; TREATMENT PLANNING; UPREGULATION; VALIDATION PROCESS;

ADULT; AGED; CARCINOMA, PAPILLARY; CELLS, CULTURED; CYSTADENOCARCINOMA, SEROUS; EPITHELIUM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; OVARY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERINE ENDOPEPTIDASES; TUMOR MARKERS, BIOLOGICAL;

EID: 4544224142     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20408     Document Type: Article

References (66)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics. CA Cancer J Clin 2003;53:5-26
2. DiSaia PJ, Creasman WT, eds. Epithelial ovarian cancer. Clinical gynecologic oncology. St. Louis: Mosby Year Book. 1997, 282-350.
3. Ismail RS, Baldwin RL, Fang J, Browning D, Karlan BY, Gasson JC, Chang DD. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res 2000;60:6744-9.
4. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, Hampton GM. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001;98:1176-81.
5. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, Misek DE, Wu R, Zhai Y, Darrah DM, Reed H, Ellenson LH, et al. Gene expression in ovarian cancer reflects both morphology and biologic behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002;62:4722-9.
6. Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, Cho, KR, Riggins GJ, Morin PJ. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 2000;60:6281-7.
7. Ono K, Tanaka T, Tsunoda T, Kitahara O, Kihara C, Okamoto A, Ochiai, K, Takagi T, Nakamura Y. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 2000;60:5007-11.
8. Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, Keeney G, Roche P, et al. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res 2001;61:5895-904.
9. Hough CD, Cho KR, Zonderman AB, Schwanz DR, Morin PJ. Coordinately upregulated genes in ovarian cancer. Cancer Res 2001;6:3869-76.
10. Shridhar V, Sen A, Chien J, Staub J, Avula R, Kovats S, Lee J, Lillie J, Smith DT. Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. Cancer Res 2002;62:262-70.
11. Jazaeri AA, Lu K, Schmandt R, Harris CP, Rao PH, Sotiriou C, Chandramouli GV, Gershenson DM, Liu ET. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog 2003;36:53-9.
12. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, et al. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47.
13. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Van de Rijn M, Jeffrey SS, Thorsen T, Quist H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
14. Zorn KK, Jazaeri AA, Awtrey CS, Gardner GJ, Mok SC, Boyd J, Birrer MJ. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res 2003;9:4811-8.
15. + cytotoxic T lymphocytes by acid-eluted peptide pulsed autologous dendritic cells. Obstet Gynecol 2000;96:422-30.
16. Fuchtner C, Emma DA, Manetta A, Gamboa G, Bernstein R, Liao SY. Characterization of a human ovarian carcinoma cell line: UCI 101. Gynecol Oncol 1993;48:203-9.
17. Gamboa G, Carpenter PM, Podnos YD, Dorion G, Iravani L, Bolton D, Mascarello JT, Manetta A. Characterization and development of UCI 107, a primary human ovarian carcinoma cell line. Gynecol Oncol 1995;58:336-43.
18. Zhan F, Tian E, Bumm K, Smith R, Barlogie B, Shaughnessy J Jr. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 2002;99:1745-57.
19. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98:5116-21.
20. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-8.
21. Packeisen J, Kaup-Franzen C, Knieriem HJ. Detection of surface antigen 17-1A in breast and colorectal cancer. Hybridoma 1999;18:37-40.
22. Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;16:1788-94.
23. Maatta M, Virtanen I, Burgeson R, Autio-Harmainen H. Comparative analysis of the distribution of laminin chains in the basement membranes in some malignant epithelial tumors: the alpha 1 chain of laminin shows a selected expression pattern in human carcinomas. J Histochem Cytochem 2001;49:711-26.
24. Casey RC, Skubitz AP. CD44 and beta1 integrins mediate ovarian carcinoma cell migration toward extracellular matrix proteins. Clin Exp Metastasis 2000;18:67-75.
25. Yoshida Y, Hosokawa K, Dantes A, Kotsuji F, Kleinman HK, Amsterdam A. Role of laminin in ovarian cancer tumor growth and metastasis via regulation of Mdm2 and Bcl-2 expression. Int J Oncol 2001;18:913-21.
26. Koshikawa N, Moriyama K, Takamura H, Mizushima H, Nagashima Y, Yanoma S, Miyazaki K. Overexpression of laminin gamma 2 chain monomer in invading gastric carcinoma cells. Cancer Res 1999;59:5596-601.
27. Vollmers HP, Imhof BA, Braun S, Waller CA, Schirrmacher V, Birchmeier W. Monoclonal antibodies which prevent experimental lung metastases. Interference with the adhesion of tumour cells to laminin. FEES Lett 1984;172:17-20.
28. Iwamoto Y, Robey FA, Graf J, Sasaki M, Kleinman HK, Yamada Y, Martin GR. YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 1987;238:1132-4.
29. Linnenbach AJ, Seng BA, Wu S, Robbins S, Scollon M, Pyre JJ, Druck T, Huebner K. Retroposition in a family of carcinoma-associated antigen genes. Mol Cell Biol 1993;13:1507-15.
30. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warriaar SO. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 1994;125:437-46.
31. Morita K, Furuse M, Fujimoto K, Tsukita S. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci USA 1999;96:511-6.
32. McClane BA. The complex interactions between Clostridium perfringens enterotoxin and epithelial tight junctions. Toxicon 2001;39:1781-91.
33. Long H, Crean CD, Lee WH, Cummings OW, Gabig TG. Expression of Clostridium perfringens enterotoxin receptors claudin 3 and claudin 4 in prostate cancer epithelium. Cancer Res 2001;61:7878-81.
34. Ganesh S, Sier CF, Griffioen G, Vloedgraven HJ, de Boer A, Welvaart K, van de Velde CJ, van Krieken JH, Verheijen JH, Lamers CB, Lamers CBHW. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1995;54:4065-71.
35. Hasina R, Hulett K, Bicciato S, Di Bello C, Petruzzelli GJ, Lingen MW. Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression. Cancer Res 2003;63:555-9.
36. Dickinson JL, Bates EJ, Ferrante A, Antalis TM. Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biologic function. J Biol Chem 1995;270:27894-904.
37. Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Janicke F, Graeff H. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 1994;5:401-9.
38. Schmalfeldt B, Kuhn W, Reuning U, Pache L, Dettmar P, Schmitt M, Janicke F, Hofler H, Graeff H. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res 1995;55:3958-63.
39. Chambers SK, Ivins CM, Carcangiu ML. Expression of plasminogen activator inhibitor-2 in epithelial ovarian cancer: a favorable prognstic factor related to the actions of CSF-1. Int J Cancer 1997;74:71-5.
40. Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res 1997;3:999-1007.
41. Droz D, Zachar D, Charbit L, Gogusev J, Chretien Y, Iris L. Expression of the human nephron differentiation molecules in renal cell carcinoma. Am J Pathol 1990;137:895-905.
42. Raife TJ, Lager DJ, Kemp JD, Dick FR. Expression of CD24 (BA-1) predicts monocytic lineage in acute myeloid leukemia. Am J Clin Pathol 1994;101:296-9.
43. Jackson D, Waibel R, Weber E, Bell J, Stahel RA. CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas. Cancer Res 1992;52:5264-70.
44. Huang LR, Hsu HC. Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation. Cancer Res 1995;55:4717-21.
45. Senner V, Sturm A, Baur I, Schrell UH, Distel L, Paulus W. CD24 promotes invasion of glioma cells in vivo. J Neuropathol Exp Neurol 1999;58:795-802.
46. Fogel M, Friederichs J, Zeller Y, Husar M, Smirnov A, Roitman L, Altevogt P, Sthoeger ZM. CD24 is a marker for human breast carcinoma. Cancer Lett 1999;143:87-94.
47. Aigner S, Sthoeger ZM, Fogel M, Weber E, Zam J, Ruppert M, Zeller Y, Vestweber D, Stahe R, Sammar M, Altevogt P. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 1997;89:3385-95.
48. Aigner S, Ramos CL, Hafezi-Moghadam A, Lawrence MB, Friederichs J, Altevogt P, Ley K. CD24 mediates rolling of breast carcinoma cells on P-selectin. EMBO J 1998;12:1241-51.
49. Friederichs J, Zeller Y, Hafezi-Moghadam A, Grone HJ, Ley K, Altevogt P. The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res 2000;60:6714-22.
50. Kristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C, Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 2002;161:1215-21.
51. Bratt T. Lipocalins and cancer. Biochim Biophys Acta 2000;1482:318-26.
52. Flower DR. The lipocalin protein family: structure and function. Biochem J 1996;318:1-14.
53. Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruszniewski P, Sauvanet A, Lemoine NR. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol 2002;160:1745-54.
54. Seth P, Porter D, Lahti-Domenici J, Geng Y, Richardson A, Polyak K. Cellular and molecular targets of estrogen in normal human breast tissue. Cancer Res 2002;62:4540-4.
55. Gates AJ, Barraclough R, Rudland PS. The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 1997;17:1-15.
56. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999;39:246-61.
57. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG. Osteopontin expression in lung cancer. Lung Cancer 1996;15:311-23.
58. Denhardt DT, Mistretta D, Chambers AF, Krishna S, Porter JF, Raghuram S, Rittling SR. Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clin Exp Metastasis 2003;20:77-84.
59. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002;287:1671-9.
60. Diamandis EP, Yousef GM. Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem 2002;48:1198-205.
61. Tanimoto H, Underwood LJ, Shigemasa K, Yan Yan MS, Clarke J, Parmley TH, O'Brien TJ. The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer 1999;86:2074-82.
62. Tanimoto H, Underwood LJ, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ. Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention. Tumor Biol 2001;22:104-14.
63. Tanimoto H, Underwood LJ, Shigemasa K, Parmley TH, O'Brien TJ. Increased expression of protease M in ovarian tumors. Tumor Biol 2001;22:11-8.
64. Diamandis EP, Scorilas A, Fracchioli S, Van Gramberen M, De Bruijn H, Henrik A, Soosaipillai A, Grass L, Yousef GM, Stenman UH, Massobrio M, Van Der Zee AG, et al. Human kallikiein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 2003;21:1035-43.
65. Cannon MJ, O'Brien TJ, Underwood LJ, Crew MD, Bondurant KL, Santin AD. Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer. Expert Rev Anticancer Ther 2002;2:97-105.
66. Liu Y, Ganesan TS. Tumour suppressor genes in sporadic epithelial ovarian cancer. Reproduction 2002;123:341-53.